Physician profile
Robert Lawrence Helm
NPI 1639732241
$7,273.43
in general payments reported to CMS, 2019-2025
19 companies · $2,248 in 2025
The $2,248 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $138 · 2022: $2,932 · 2023: $914 · 2024: $897 · 2025: $2,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,645 · Travel and Lodging: $1,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,644.50 |
| Travel and Lodging | $1,414.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,535.19 | 2022-2024 | |
| Procept Biorobotics Corporation | $1,688.82 | 2025 | |
| Urogen Pharma, INC. | $436.10 | 2022-2024 | Jelmyto |
| Dendreon Pharmaceuticals LLC | $282.59 | 2019-2020 | |
| Baxter Healthcare | $223.19 | 2024 | Perclot |
| Coloplast Corp | $164.66 | 2024 | |
| Intuitive Surgical, INC. | $155.67 | 2023-2025 | |
| Teleflex LLC | $147.35 | 2025 | Urolift |
| Calyxo, INC. | $137.03 | 2025 | Cvac Aspiration System |
| Astellas Pharma US INC | $112.35 | 2023 | Xtandi |
| Abbvie INC. | $95.49 | 2023 | |
| Endo USA, INC. | $93.16 | 2024-2025 | Xiaflex, Aveed |
| Pfizer INC. | $47.69 | 2025 | |
| Janssen Biotech, INC. | $46.81 | 2024-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $38.08 | 2024 | Gemtesa, Orgovyx |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $21.41 | 2025 | |
| Tolmar, INC. | $17.93 | 2024 | |
| Ferring Pharmaceuticals INC. | $16.34 | 2025 | Adstiladrin |
| Sandoz INC. | $13.57 | 2025 | Jubbonti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Helm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.